720
Views
7
CrossRef citations to date
0
Altmetric
Review Article

Neuroendocrine gastro-enteropancreatic tumors – from eminence based to evidence-based medicine – A Scandinavian view

Pages 727-739 | Received 19 Mar 2015, Accepted 19 Mar 2015, Published online: 08 Apr 2015

References

  • IMModlin, KOberg, DCChung, RTJensen, WWde Herder, RVThakker, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61–72.
  • JCYao, MHassan, APhan, CDagohoy, CLeary, JEMares, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72.
  • FTBosman, FCarneiro. WHO Classification of Tumours, pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2010.
  • ASundin, MPVullierme, GKaltsas, UPlockinger. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90:167–83.
  • MPerri, PErba, DVolterrani, ELazzeri, GBoni, MGrosso, et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 2008;52:323–33.
  • YKrausz, NFreedman, RRubinstein, ELavie, MOrevi, STshori, et al. Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (111) In-DTPA-octreotide (OctreoScan(R)). Mol Imaging Biol 2011;13:583–93.
  • MGabriel, CDecristoforo, DKendler, GDobrozemsky, DHeute, CUprimny, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508–18.
  • HOrlefors, ASundin, UGarske, CJuhlin, KOberg, BSkogseid, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392–400.
  • KPKoopmans, OCNeels, IPKema, PHElsinga, WJSluiter, KVanghillewe, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008;26:1489–95.
  • TBinderup, UKnigge, ALoft, BFederspiel, AKjaer. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978–85.
  • LTaupenot, KLHarper, DTO’Connor. The chromogranin-secretogranin family. N Engl J Med 2003;348:1134–49.
  • IMModlin, BIGustafsson, SFMoss, MPavel, AVTsolakis, MKidd. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010;17:2427–43.
  • SWelin, MStridsberg, JCunningham, DGranberg, BSkogseid, KOberg, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009;89:302–7.
  • WWde Herder. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:33–41.
  • AScarpa, WMantovani, PCapelli, SBeghelli, LBoninsegna, RBettini, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23:824–33.
  • OHentic, ACouvelard, VRebours, MZappa, SDokmak, PHammel, et al. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer 2011;18:51–9.
  • RKianmanesh, DO’Toole, ASauvanet, PRuszniewski, JBelghiti. Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases. J Chir 2005;142:208–19.
  • JEriksson, PStalberg, ANilsson, JKrause, CLundberg, BSkogseid, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 2008;32:930–8.
  • PRuszniewski, PRougier, ARoche, PLegmann, ASibert, SHochlaf, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993;71:2624–30.
  • TJVogl, TGruber, NNNaguib, RHammerstingl, NENour-Eldin. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. Ajr 2009;193:941–7.
  • DJKwekkeboom, JMueller-Brand, GPaganelli, LBAnthony, SPauwels, LKKvols, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:62S–6S.
  • IMModlin, MPavel, MKidd, BIGustafsson. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169–88.
  • KOberg. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000;62:92–7.
  • SEkeblad, ASundin, ETJanson, SWelin, DGranberg, HKindmark, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986–91.
  • NCTurner, SJStrauss, DSarker, RGillmore, AKirkwood, AHackshaw, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010;102:1106–12.
  • JCYao, MHShah, TIto, CLBohas, EMWolin, EVan Cutsem, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.
  • ERaymond, LDahan, JLRaoul, YJBang, IBorbath, CLombard-Bohas, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501–13.
  • ARinke, HHMuller, CSchade-Brittinger, KJKlose, PBarth, MWied, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656–63.
  • MECaplin, MPavel, JBCwikla, ATPhan, MRaderer, ESedlackova, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371:224–33.
  • RSYalow, SABerson. Immunoassay of endogenous plasma insulin in man 1960. Obesity Res 1996;4:583–600.
  • KOberg. Peptide hormone markers in endocrine gastrointestinal tumorsI. Acta Univers Upsal 1981;30:383.
  • KOberg, LGrimelius, GLundqvist, LELorelius. Update on pancreatic polypeptide as a specific marker for endocrine tumours of the pancreas and gut. Acta Med Scand 1981;210:145–52.
  • KOberg, LWide, HBostrom. HCG-alpha and HCG-beta subunits as tumour markers during therapy in a case with so-called "non-functioning" islet cell tumour. Acta Med Scand 1981;210:231–3.
  • KOberg, OWalinder, HBostrom, GLundqvist, LWide. Peptide hormone markers in screening for endocrine tumors in multiple endocrine adenomatosis type I. Am J Med 1982;73:619–30.
  • LWide. Radioimmunoassays employing immunosorbents. Acta Endocrinol Suppl 1969;142:207–21.
  • KOberg, GLundqvist. Meal-stimulated and atropine-inhibited secretion of pancreatic polypeptide in healthy subjects, members of MEA I families and patients with malignant endocrine tumours of the gastrointestinal tract. Regul Pept 1983;5:273–82.
  • ETheodorsson-Norheim, KOberg, SRosell, HBostrom. Neurotensinlike immunoreactivity in plasma and tumor tissue from patients with endocrine tumors of the pancreas and gut. Gastroenterology 1983;85:881–9.
  • INorheim, ETheodorsson-Norheim, EBrodin, KOberg, GLundqvist, SRosell. Antisera raised against eledoisin and kassinin detect elevated levels of immunoreactive material in plasma and tumor tissues from patients with carcinoid tumors. Regul Pept 1984;9:245–57.
  • INorheim, EWilander, KOberg, ETheodorsson-Norheim, MLLundqvist, PLindgren, et al. Tachykinin production by carcinoid tumours in culture. Eur J Cancer Clin Oncol 1987;23:689–95.
  • INorheim, ETheodorsson-Norheim, EBrodin, KOberg. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986;63:605–12.
  • KOberg, GLundqvist, LWide. Treatment of the carcinoid syndrome with SMS 201-995;a somatostatin analogue. Scand J Gastroenterol 1986;119:191–2.
  • KOberg, ETheodorsson-Norheim, INorheim. Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements. Scand J Gastroenterol 1987;22:1041–8.
  • BEriksson, HArnberg, KOberg, UHellman, GLundqvist, CWernstedt, et al. A polyclonal antiserum against chromogranin A and B–a new sensitive marker for neuroendocrine tumours. Acta Endocrinol 1990;122:145–55.
  • DTO’Connor, LJDeftos. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986;314:1145–51.
  • BEriksson, HArnberg, KOberg, UHellman, GLundqvist, CWernstedt, et al. Chromogranins–new sensitive markers for neuroendocrine tumors. Acta Oncol 1989;28:325–9.
  • HBlaschko, RSComline, FHSchneider, MSilver, ADSmith. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 1967;215:58–9.
  • MStridsberg, UHellman, EWilander, GLundqvist, KHellsing, KOberg. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993;139:329–37.
  • LLarsson, JAlumets, BEriksson, RHåkansson, GLunqvist, KÖberg, et al. Antiserum directed against both chromogranin A and B (CAB) is a general marker for peptide hormone producing endocrine cells and toumors. Endoc Pathol 1992;3:14–22.
  • LLundin, INorheim, JLandelius, KOberg, ETheodorsson-Norheim. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 1988;77:264–9.
  • AThorson, GBiorck, GBjorkman, JWaldenstrom. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J 1954;47:795–817.
  • KFuna, VPapanicolaou, CJuhlin, JRastad, GAkerstrom, CHHeldin, et al. Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 1990;50:748–53.
  • JWaltenberger, LLundin, KOberg, EWilander, KMiyazono, CHHeldin, et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 1993;142:71–8.
  • AChaudhry, KOberg, EWilander. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 1992;13:27–35.
  • TCui, AVTsolakis, SCLi, JLCunningham, TLind, KOberg, et al. Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas. Eur J Endocrinol 2013;168:253–61.
  • SCLi, AEssaghir, CMartijn, RVLloyd, JBDemoulin, KOberg, et al. Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. Mod Pathol 2013;26:685–96.
  • AHemmingsson, PGLindgren, LELorelius, KOberg. Diagnosis of endocrine gastrointestinal tumours. Acta Radiol Diagn 1981;22:657–62.
  • TAndersson, BEriksson, AHemmingsson, PGLindgren, KOberg. Angiography, computed tomography, magnetic resonance imaging and ultrasonography in detection of liver metastases from endocrine gastrointestinal tumours. Acta Radiol 1987;28:535–9.
  • TAndersson, BEriksson, PGLindgren, EWilander, KOberg. Percutaneous ultrasonography-guided cutting biopsy from liver metastases of endocrine gastrointestinal tumors. Ann Sur 1987;206:728–32.
  • BEriksson, MBergstrom, ALilja, HAhlstrom, BLangstrom, KOberg. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol (Madr) 1993;32:189–96.
  • JEWestlin, ETJanson, HArnberg, HAhlstrom, KOberg, SNilsson. Somatostatin receptor scintigraphy of carcinoid tumours using the 111In-DTPA-D-Phe1]-octreotide. Acta Oncol (Madr) 1993;32:783–6.
  • JEWestlin, HAhlstrom, JYla-Jaaski, KOberg, SNilsson. Three-dimensional OctreoScan111 SPECT of abdominal manifestation of neuroendocrine tumours. Acta Oncol (Madr) 1993;32:171–6.
  • KMKalkner, ETJanson, SNilsson, SCarlsson, KOberg, JEWestlin. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radiology uptake and tumor markers. Cancer Res 1995;55:5801s–4s.
  • ETJanson, JEWestlin, BEriksson, HAhlstrom, SNilsson, KOberg. 111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994;131:577–81.
  • HAhlstrom, BEriksson, MBergstrom, PBjurling, BLangstrom, KOberg. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995;195:333–7.
  • HOrlefors, ASundin, UGarske, CJuhlin, KOberg, BSkogseid, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392–400.
  • BEriksson, MBergstrom, HOrlefors, ASundin, KOberg, BLangstrom. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 2000;44:68–76.
  • ASundin, BEriksson, MBergstrom, BLangstrom, KOberg, H. PEOrleforsT in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci 2004;1014:246–57.
  • BEriksson, HOrlefors, KOberg, ASundin, MBergstrom, BLangstrom. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 2005;19:311–24.
  • KOberg. Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2012;2:448–58.
  • BSkogseid, KOberg, LBenson, PGLindgren, LELorelius, GLundquist, et al. A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: five years experience. J Clin Endocrinol Metab 1987;64:1233–40.
  • CLarsson, BSkogseid, KOberg, YNakamura, MNordenskjold. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85–7.
  • KOberg, HBostrom, JFahrenkrug, JFDymling, OBShaffalitsky de Muckadell, GLundqvist. Streptozotocin treatment of a pancreatic tumour producing VIP and gastrin associated with Verner-Morrison syndrome. Acta Med Scand 1979;206:223–7.
  • KOberg, GLundqvist, HBoström. The effect of Streptozotocin in the treatment of endocrine pancreatic tumors and carcinoids. In MKAgrewall, editor. Streptozotocin. North Holland: Elsevier; 1982.
  • KOberg, KFuna, GAlm. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983;309:129–33.
  • KFuna, GVAlm, LRonnblom, KOberg. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. Clin Exp Immunol 1983;53:716–24.
  • EWilander, ABengtsson, INorheim, KOberg. Interferon-induced nuclear DNA alterations in malignant carcinoid tumors in vivo. J Natl Cancer Inst 1986;76:429–33.
  • BEriksson, KOberg, GAlm, AKarlsson, GLundqvist, AMagnusson, et al. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Cancer Treat Rep 1987;71:31–7.
  • PBurman, THTotterman, KOberg, FAKarlsson. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 1986;63:1086–90.
  • KOberg, AJakobsson, GGustafsson, EWilander, GLundqvist, MStridsberg. WDHA-syndrome due to a VIP and NPY producing ganglioneuroblastoma. Treatment with SMS 201-995, a somatostatin analogue. Scand J Gastroenterol 1986;Vol 21:228–9.
  • KOberg, BEriksson, INorheim. Treatment of malignant neuroendocrine gut and pancreatic tumors with the somatostatin analogue SMS 201-995. Proceedings of Concensus Meeting on Somatostatin analogue SMS 201-995, Sandoz. Phoenix, Arizona, USA; 1987. pp 89–92.
  • BEriksson, KOberg, TAndersson, GLundqvist, LWide, EWilander. Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995. Scand J Gastroenterol 1988;23:508–12.
  • KOberg, INorheim, ETheodorsson, HAhlman, GLundqvist, LWide. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. J Clin Endocrinol Metab 1989;68:796–800.
  • KOberg, GVAlm. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors. J Interferon Res 1989;9:S45–9.
  • KOberg, GAlm, AMagnusson, GLundqvist, ETheodorsson, LWide, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989;81:531–5.
  • LERonnblom, GVAlm, KEOberg. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990;227:207–10.
  • BEriksson, BSkogseid, GLundqvist, LWide, EWilander, KOberg. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65:1883–90.
  • CMakridis, KOberg, CJuhlin, JRastad, HJohansson, LELorelius, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990;14:377–83.
  • DGrander, KOberg, MLLundqvist, ETJanson, BEriksson, SEinhorn. Interferon-induced enhancement of 2’,5’-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet 1990;336:337–40.
  • LERonnblom, GVAlm, KEOberg. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178–83.
  • EMTiensuu Janson, HAhlstrom, TAndersson, KEOberg. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992;28A:1647–50.
  • ETJanson, KOberg. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol (Madr) 1993;32:225–9.
  • ETJanson, LHolmberg, MStridsberg, BEriksson, ETheodorsson, EWilander, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685–90.
  • BEriksson, ETJanson, NDBax, MMignon, RMorant, POpolon, et al. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. Digestion 1996;57:77–80.
  • BEriksson, JRenstrup, HImam, KOberg. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997;8:1041–4.
  • BKEriksson, EGLarsson, BMSkogseid, AMLofberg, LELorelius, KEOberg. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293–301.
  • MAfargan, ETJanson, GGelerman, RRosenfeld, OZiv, OKarpov, et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 2001;142:477–86.
  • MLFjallskog, DPGranberg, SLWelin, CEriksson, KEOberg, ETJanson, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101–7.
  • ANWymenga, BEriksson, PISalmela, MBJacobsen, EJVan Cutsem, RHFiasse, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999;17:1111.
  • SVWelin, ETJanson, ASundin, MStridsberg, ELavenius, DGranberg, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004;151:107–12.
  • DLBushnellJr, TMO’Dorisio, MSO’Dorisio, YMenda, RJHicks, EVan Cutsem, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010;28:1652–9.
  • JLeja, HDzojic, EGustafson, KOberg, VGiandomenico, MEssand. A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy. Clin Cancer Res 2007;13:2455–62.
  • JCYao, MHShah, TIto, CLBohas, EMWolin, EVan Cutsem, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.
  • MEPavel, JDHainsworth, EBaudin, MPeeters, DHorsch, REWinkler, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005–12.
  • SEkeblad, BSkogseid, KDunder, KOberg, BEriksson. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008;14:7798–803.
  • SWelin, HSorbye, SSebjornsen, SKnappskog, CBusch, KOberg. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011;117:4617–22.
  • ONorlen, PStalberg, KOberg, JEriksson, JHedberg, OHessman, et al. Long-Term Results of Surgery for Small Intestinal Neuroendocrine Tumors at a Tertiary Referral Center. World J Surg 2012;36:1419–31.
  • LKKvols, KEOberg, TMO’Dorisio, PMohideen, WWde Herder, RArnold, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer 2012;19:657–66.
  • KOberg, UKnigge, DKwekkeboom, APerren. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii124–30.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.